Homepage

Read about the Oxford Vaccine Centre’s COVID-19 vaccine trial.

Com-COV3: Vaccine study to research third dose booster options for 12-to-15 year-olds –find your closest study site and read the press release

Recruiting Now: Help us investigate the first ever vaccine for Invasive Non-Typhoid Salmonella (iNTS) – The SALVO Trial

If you are aged 18 to 55 years old, in good health and live in the Oxford area, then you may be eligible to take part.

Image depicting two vials of different Covid-19 vaccines

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

Oral paratyphoid vaccine to begin human trials

The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

Professor Sue Ann Costa Clemens awarded an Honorary CBE

Congratulations to Professor Sue Ann Costa Clemens for her Honarary CBE award for her positive contribution towards public health. Here at the Oxford Vaccine Group and the Paediatrics department, we are extremely proud of what Sue and her team have achieved.

Take part in a clinical trial – see a list of all the trials we are currently recruiting to.

Child being vaccinated

Non-COVID research statement

The Oxford Vaccine Group will be continuing with some of our non-COVID research, particularly our paediatric studies, during the COVID-19 pandemic. This is because as part of these studies we give babies their routine primary immunisations on behalf of their GPs. This reduces the administrative burden on the NHS, allowing them to free up capacity and prioritise their workload to be focused on doing what is necessary to manage the response to the COVID-19 pandemic. The participants also benefit from having the vaccines in the safety of their homes or a convenient location.

Vaccine Knowledge

The Vaccine Knowledge Project aims to be a source of independent information about vaccines and infectious diseases.

See more

Research

Vaccines are a key component of global health policy and are essential in the defence of the health of young children. Our research focuses on the development and evaluation of new and improved vaccines.

Explore

Events and Training

We are committed to providing high quality education and training, together with research updates for medical professionals and all those involved in the area of vaccines and paediatric and adult infectious diseases.

Learn

Get involved

There are a number of ways in which you can get involved in our research, inform our research and find out more about our work. To find out more about any of these options, follow the link below.

Participate

Latest publications

Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus.
Journal article

Sheerin D. et al, (2022), Cell Biosci, 12
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article

Li G. et al, (2022), Lancet, 399, 2212 - 2225
Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.
Journal article

Rollier CS. et al, (2022), Vaccine
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article

Shaw RH. et al, (2022), Lancet Respir Med
Viral vector vaccines.
Journal article

McCann N. et al, (2022), Curr Opin Immunol, 77

Upcoming events

IIC 2022 - Hot Topics In Infection And Immunity In Children

Thursday, 30 June 2022 to Saturday, 02 July 2022

IIC – The ESPID-Oxford Course is a residential training course covering topics in paediatric infection for paediatric infectious diseases trainees and trainers, and for all those who manage children with infections. This will be the 19th edition of the course.

Virtual Influenza Update Training

Wednesday, 21 September 2022, 10am to 12.30pm

This training is for general practice nurses and other health professionals who as part of their role already administer and promote / advise about influenza vaccines. The training will cover the theory of the influenza programme. ** Please note that we will not be covering the local logistics of delivering the 2022/23 influenza programme **

National Immunisation Schedule Evaluation Consortium

OVG is part of the National Immunisation Schedule Evaluation Consortium; a collaboration between a network of Academic Clinical Research groups and the UK Health Security Agency, with a brief of conducting clinical research relevant to UK immunisation policy

More about NISEC

We’ve made a vaccine, now you can make the difference

We’ve heard about how effective vaccines are, but what do we need for them to have the biggest impact on the coronavirus pandemic?

How to make a vaccine in record time

Vaccines usually take decades to develop – so how is Oxford University's ChAdOx1 nCoV-1 vaccine trial moving so quickly? It comes down to careful planning, extraordinary logistics and a whole lot of help from partners around the world.